Flucelvax
Biological
Seqirus USA Inc
Total Payments
$4.1M
Transactions
5,319
Doctors
4,311
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $99,979 | 4,795 | 4,063 |
| 2019 | $3.8M | 157 | 0 |
| 2018 | $217,198 | 286 | 175 |
| 2017 | $1,178 | 81 | 81 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.0M | 176 | 96.8% |
| Food and Beverage | $109,975 | 5,089 | 2.7% |
| Travel and Lodging | $21,306 | 53 | 0.5% |
| Consulting Fee | $1,200 | 1 | 0.0% |
Payments by Type
Research
$4.0M
176 transactions
General
$132,482
5,143 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine QIVc and a United States Licensed Quadrivalent Influenza Virus Vaccine QIV in Healthy Subjects 6 Months Through 47 Months | Seqirus USA Inc | $3.7M | 0 |
| Adjuvanted influenza Vaccination and Morbidity and Mortaliy in US Nursing Homes | Seqirus USA Inc | $127,605 | 0 |
| A Phase III, Randomized, Observer-blind, Multicenter, Non-inferiority Study To Evaluate The Immunogenicity And Safety Of Seqirus QIVc and a Licensed QIV Comparator Vaccine in Healthy Subjects 6 Months Through 47 Months of Age | Seqirus USA Inc | $47,968 | 0 |
| A Prospective Observational Safety Study on Pregnancy Outcomes in Women Immunized With Seasonal Cell Culture Influenza Trivalent TIVc or Quadrivalent QIVc Vaccine During Pregnancy | Seqirus USA Inc | $30,063 | 0 |
| V13010 is A Phase III, Randomized, Observer-blind, Multicenter, Non-inferiority Study To Evaluate The Immunogenicity And Safety Of Seqirus QIVc and a Licensed QIV Comparator Vaccine in Healthy Subjects 6 Months Through 47 Months of Age | Seqirus USA Inc | $10,200 | 0 |
| A Phase III, Stratified, Randomized, Double-Blind, Multicenter, NonInferiority Study to Evaluate the Safety and Immunogenicity of a Cell-based Quadrivalent Subunit Influenza Virus Vaccine and Cell-based Trivalent Subunit Influenza Virus Vaccines in Adults Ages 18 Years of Age | Seqirus USA Inc | $8,000 | 0 |
| The study is a population based prospective cohort study designed to collect data on pregnancy outcomes and events of interest among women immunized with the TIVc or QIVc vaccine during pregnancy. | Seqirus USA Inc | $100.00 | 1 |
Top Doctors Receiving Payments for Flucelvax — Page 7
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , NP | Pediatrics | Albany, NY | $54.14 | 2 |
| , MD | Pediatrics | Anderson, IN | $54.00 | 1 |
| Ashley Miller | Medical | Lincoln, NE | $53.96 | 2 |
| , D.O | General Practice | Pace, FL | $53.96 | 2 |
| , MD | Pediatrics | Lincoln, NE | $53.96 | 2 |
| , FNP-BC | Family | Eureka, IL | $53.90 | 2 |
| , M.D | Specialist | Bloomington, IL | $53.89 | 2 |
| , MD | Pediatrics | Castleton, NY | $53.55 | 2 |
| , M.D | Pediatrics | Castleton, NY | $53.55 | 2 |
| , M.D | Pediatrics | Huntington, NY | $53.55 | 2 |
| , MD | Pediatrics | Washington, DC | $53.48 | 3 |
| , MD | Pediatrics | West Palm Beach, FL | $53.46 | 2 |
| , M.D | Internal Medicine | Arcadia, CA | $53.33 | 3 |
| , MD | Pediatric Emergency Medicine | Saint Louis, MO | $53.03 | 2 |
| , MD | Pediatrics | Saint Louis, MO | $53.03 | 2 |
| , MD | Pediatric Emergency Medicine | Saint Louis, MO | $53.03 | 2 |
| , M.D | Pediatrics | Olympia, WA | $52.98 | 2 |
| , M.D | Pediatrics | Olympia, WA | $52.97 | 2 |
| , DO | Pediatrics | North Riverside, IL | $52.94 | 2 |
| , FNP-C | Registered Nurse | North Riverside, IL | $52.93 | 2 |
| Lauren Jackson | Nurse Practitioner | Westerville, OH | $52.77 | 3 |
| , MD | Pediatrics | Chicago, IL | $52.59 | 2 |
| , MD | General Practice | Lakewood, WA | $52.56 | 2 |
| , MD | Student in an Organized Health Care Education/Training Program | New Rochelle, NY | $52.54 | 2 |
| , D.O | Pediatrics | New Rochelle, NY | $52.53 | 2 |
Ad
Manufacturing Companies
- Seqirus USA Inc $4.1M
Product Information
- Type Biological
- Total Payments $4.1M
- Total Doctors 4,311
- Transactions 5,319
About Flucelvax
Flucelvax is a biological associated with $4.1M in payments to 4,311 healthcare providers, recorded across 5,319 transactions in the CMS Open Payments database. The primary manufacturer is Seqirus USA Inc.
Payment data is available from 2017 to 2024. In 2024, $99,979 was paid across 4,795 transactions to 4,063 doctors.
The most common payment nature for Flucelvax is "Unspecified" ($4.0M, 96.8% of total).
Flucelvax is associated with 7 research studies, including "A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine QIVc and a United States Licensed Quadrivalent Influenza Virus Vaccine QIV in Healthy Subjects 6 Months Through 47 Months" ($3.7M).